专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1991019000A1 A MONOCLONAL ANTIBODY AGAINST THE GAG PROTEIN PRECURSOR p55 OF HUMAN IMMUNODEFICIENCY VIRUS 审中-公开
标题翻译：抗人类免疫缺陷病毒的GAG蛋白前体p55的单克隆抗体
公开(公告)号：WO1991019000A1
公开(公告)日：1991-12-12
申请号：PCT/EP1991000947
申请日：1991-05-21
申请人： GRUPPO LEPETIT S.P.A. , NOLLI, Maria, Luisa, Cesira , SARUBBI, Edoardo, Giacomo
发明人： GRUPPO LEPETIT S.P.A.
IPC分类号： C12P21/08
CPC分类号： C07K14/005 , C07K16/1054 , C12N2740/16222
摘要： A monoclonal antibody showing specific reactivity against the precursor protein named p55 which is cleaved by HIV-1 protease into smaller structural protein. The antibody of this invention shows specific reactivity against an epitope of the p55 protein which corresponds to the cleavage site by HIV-1 protease which generates the p24 and p17 structural proteins. The specific antibody is an IgG1 protein with a molecular weight of the order of 150,000 Dalton produced by a hybridoma deriving from the fusion of spleen cells of animals immunized with a cloned fused protein containing a p55 fragment which includes the p24/p17 cleavage site and a myeloma cell line. The specific antibody is useful for monitoring HIV-1 exposure, for isolation and purification of natural or synthetic peptides containing the p55 sequence or a fragment thereof which include the p24/p17 cleavage site and for screening substances for HIV-1 protease inhibitory activity.
摘要翻译：显示出与HIV-1蛋白酶切割成较小结构蛋白的名为p55的前体蛋白的特异性反应性的单克隆抗体。本发明的抗体显示出对应于产生p24和p17结构蛋白的HIV-1蛋白酶的切割位点的p55蛋白表位的特异性反应性。特异性抗体是IgG1蛋白，其分子量为150,000道尔顿产生的杂交瘤，该杂交瘤来源于用包含p24 / p17切割位点的p55片段的克隆融合蛋白免疫的动物的脾细胞融合，骨髓瘤细胞系。特异性抗体可用于监测HIV-1暴露，用于分离和纯化含有p55序列或其片段的天然或合成肽，其包括p24 / p17切割位点和用于筛选HIV-1蛋白酶抑制活性的物质。

2. 发明申请

WO2004031370A1 PROCEDURE FOR THE LARGE-SCALE T-LYMPHOCYTES CULTURE IN A HOMOGENEOUS SYSTEM 审中-公开
标题翻译：均匀系统中大规模T淋巴细胞培养的程序
公开(公告)号：WO2004031370A1
公开(公告)日：2004-04-15
申请号：PCT/EP2003/011024
申请日：2003-10-06
申请人： ABIOGEN PHARMA S.P.A. , TRASCIATTI, Silvia , NOLLI, Maria, Luisa , CAVENAGHI, Luigi , DE BERNARDI, Nadia
发明人： TRASCIATTI, Silvia , NOLLI, Maria, Luisa , CAVENAGHI, Luigi , DE BERNARDI, Nadia
IPC分类号： C12N5/08
CPC分类号： C12N5/0694 , A61K2035/124 , C12N2501/23
摘要： The present invention refers to a procedure for the large-scale amplification of human lymphocytic cell lines for therapeutic use, consisting of a homogeneous culture system. The claimed invention also refers to the production of therapeutic doses of lymphocytic cells cultured homogeneously.
摘要翻译：本发明涉及由均质培养系统组成的用于治疗用途的人类淋巴细胞系的大规模扩增的方法。所要求保护的发明还涉及产生均匀培养的治疗剂量的淋巴细胞。

3. 发明申请

WO2009016456A3 IDIOTYPIC VACCINE 审中-公开
标题翻译：异型疫苗
公开(公告)号：WO2009016456A3
公开(公告)日：2009-08-13
申请号：PCT/IB2008001936
申请日：2008-07-24
申请人： ARETA INTERNAT S R L , DOLCETTI RICCARDO , GUIDOBONI MASSIMO , DE RE VALLI , GASPAROTTO DANIELA , CASTIGLIONI SONIA , NOLLI MARIA LUISA
发明人： DOLCETTI RICCARDO , GUIDOBONI MASSIMO , DE RE VALLI , GASPAROTTO DANIELA , CASTIGLIONI SONIA , NOLLI MARIA LUISA
IPC分类号： A61K39/29 , C07K14/18
CPC分类号： C07K16/109 , A61K39/12 , A61K39/29 , A61K2039/6081 , C07K14/005 , C07K16/4216 , C07K2317/622 , C12N2770/24222 , C12N2770/24234
摘要： The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
摘要翻译：本发明涉及重组克隆型免疫球蛋白（Ig）作为疫苗用于治疗HCV相关和非HCV相关淋巴组织增殖的用途，特别是使用具有衍生自蛋白质片段VK3-20和VK3-15的免疫原性的重组蛋白来自淋巴结增生患者的Ig轻链。

4. 发明申请

WO2009016456A2 IDIOTYPIC VACCINE 审中-公开
标题翻译：原型疫苗
公开(公告)号：WO2009016456A2
公开(公告)日：2009-02-05
申请号：PCT/IB2008/001936
申请日：2008-07-24
申请人： ARETA INTERNATIONAL S.R.L. , DOLCETTI, Riccardo , GUIDOBONI, Massimo , DE RE, Valli , GASPAROTTO, Daniela , CASTIGLIONI, Sonia , NOLLI, Maria Luisa
发明人： DOLCETTI, Riccardo , GUIDOBONI, Massimo , DE RE, Valli , GASPAROTTO, Daniela , CASTIGLIONI, Sonia , NOLLI, Maria Luisa
IPC分类号： A61K39/00
CPC分类号： C07K16/109 , A61K39/12 , A61K39/29 , A61K2039/6081 , C07K14/005 , C07K16/4216 , C07K2317/622 , C12N2770/24222 , C12N2770/24234
摘要： The invention concerns the use of recombinant clonotypic immunoglobulins (Ig) as a vaccine in the treatment of HCV-related and non HCV-related lymphoproliferations, in particular the use of recombinant proteins with immunogenic properties derived from protein segments VK3-20 and VK3-15 of Ig light chains derived from patients with lymphoproliferations.
摘要翻译：本发明涉及重组克隆型免疫球蛋白（Ig）作为疫苗在治疗HCV相关和非HCV相关淋巴增殖中的用途，特别是使用具有源自蛋白质的免疫原性的重组蛋白来自淋巴组织增生患者的Ig轻链的VK3-20和VK3-15片段。

5. 发明申请

WO2009133452A1 ANTI-HMGA1 MONOCLONAL ANTIBODIES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE QUANTITATIVE DETERMINATION OF HMGA1 审中-公开
标题翻译：抗HMGA1单克隆抗体，其制备方法及其用于定量测定HMGA1的方法
公开(公告)号：WO2009133452A1
公开(公告)日：2009-11-05
申请号：PCT/IB2009/005435
申请日：2009-04-29
申请人： ARETA INTERNATIONAL S.R.L. , FUSCO, Alfredo , ORLANDI, Antonio , NOLLI, Maria Luisa
发明人： FUSCO, Alfredo , ORLANDI, Antonio , NOLLI, Maria Luisa
IPC分类号： A61K39/00 , C07K16/18 , A61P3/08
CPC分类号： A61K39/0008 , A61K2039/5256 , C07K16/24 , C12N2710/10022
摘要： This invention concerns a panel of monoclonal antibodies against the High Mobility Group A 1 protein (HMGAl) and a process for preparing them, as well as the use of said antibodies for the quantitative determination of HMGAl in biological fluids or in protein Iy sates deriving from lymphocyte cells. This invention also concerns a diagnostic kit for assessing risk factors related to the expression of the HMGAl proteins.
摘要翻译：本发明涉及一组针对高迁移率组A 1蛋白（HMGA1）的单克隆抗体及其制备方法，以及使用所述抗体定量测定生物流体中的HMGA1或来源于蛋白质的蛋白质淋巴细胞。本发明还涉及用于评估与HMGA1蛋白表达相关的危险因素的诊断试剂盒。

6. 发明申请

WO1986001411A1 ANTI-UROKINASE MONOCLONAL ANTIBODY; ITS PRODUCTION AND USE 审中-公开
标题翻译：抗尿毒素单克隆抗体其生产和使用
公开(公告)号：WO1986001411A1
公开(公告)日：1986-03-13
申请号：PCT/EP1985000428
申请日：1985-08-21
申请人： GRUPPO LEPETIT S.P.A. , NOLLI, Maria, Luisa , CORTI, Angelo , SOFFIENTINI, Adolfo , CASSANI, Giovanni , PARENTI, Francesco
发明人： GRUPPO LEPETIT S.P.A.
IPC分类号： A61K39/395
CPC分类号： C12N9/6462 , C07K16/40 , C12Y304/21073 , G01N33/86 , G01N2333/9723
摘要： A class of new IgG1 monoclonal antibodies, directed to an epitope on human urokinase, which selectively bind to high molecualr weight urokinase (54,000), or a single-chain precursor thereof, without binding to low molecular weight urokinase (33,000) have an affinity constant for urokinase which is suitable for use in an immono-adsorption-based purification system and does not impair the enzymatic activity of urokinase. This antibody is also useful in immunoassays.
摘要翻译：一类针对人尿激酶表位选择性结合高分子量尿激酶（54,000）或其单链前体而不与低分子量尿激酶（33,000）结合的新IgG1单克隆抗体具有亲和力常数适用于基于吸烟型纯化系统的尿激酶，不影响尿激酶的酶活性。该抗体也可用于免疫测定。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式